研究与报告
白皮书、研究报告和市场数据
研究与报告
2026年9月14日•1 分钟阅读
Domestic P‑CAB drug 자큐보 shows GERD efficacy and safety in >5,500‑patient real‑world study
Oncogenic Therapeutics reports that 자큐보 (자스타프라잔시트르산염) improved GERD symptoms and was well tolerated in a real‑world study of over 5,500 patients, including those switched from PPIs.
1
研究与报告
2026年9月14日•1 分钟阅读
Yuhan Corp. and K-MediHub Sign MOU to Expand Joint New Drug Research
Yuhan Corp. has signed an MOU with Daegu‑Gyeongbuk Advanced Medical Industry Promotion Foundation (K‑MediHub) to broaden joint new‑drug projects and share research infrastructure.
研究与报告
2026年9月14日•1 分钟阅读
HLB's Riboceranib + Camrelizumab Shows Consistent Efficacy Across Ages in CARES-310 uHCC Trial
In the global Phase 3 CARES-310 study, HLB's riboceranib‑camrelizumab combo achieved a median overall survival of 21.5 months in patients under 50, outperforming sorafenib's 15.2 months, with consistent benefit across age groups.
研究与报告
2026年9月14日•1 分钟阅读
GC녹십자웰빙's RZL-012 Meets Primary Endpoints in Chinese Phase 3 Trial
GC녹십자웰빙 announced that its exclusive drug candidate RZL-012 achieved primary efficacy and safety endpoints in a pivotal Phase 3 trial in China involving 480 adults with submental fat.
研究与报告
2026年9月14日•1 分钟阅读
Korean Prime Pharma Initiates Phase 1 Trial of Cetirizine ODT (KPP-2603-T)
Korean Prime Pharma received approval to start a Phase‑1 exploratory study of its cetirizine orally disintegrating tablet (KPP‑2603‑T) in six healthy adults.
研究与报告
2026年9月14日•1 分钟阅读
Global Type 1 Diabetes Cases Projected to Rise 30% by 2049, Study Finds
A Danish research team projects worldwide type 1 diabetes patients will increase from 9.4 million to about 12.1 million by 2049, a 30% rise, with new cases up 14%.
研究与报告
2026年9月14日•1 分钟阅读
Study Finds Children of Centenarian Parents Have 42% Lower Mortality Risk
Research shows individuals with parents who lived past 100 have significantly lower risks of death, heart disease and hypertension.
研究与报告
2026年9月14日•1 分钟阅读
High Blood Sugar and Low Weight Increase Ketoacidosis Risk in SGLT2 Inhibitor Users
Patients with high glucose, low body weight or prior ketoacidosis on SGLT2 inhibitors face higher serious adverse event risk, especially during infection or acute illness.
研究与报告
2026年9月14日•1 分钟阅读
Novartis' Rhapsido Shows Liver‑Safe Efficacy in Phase 3 MS Trials
Novartis reported that its BTK inhibitor remibrutinib (Rhapsido) met primary and key secondary endpoints in two Phase 3 trials for relapsing MS, without liver safety concerns, outperforming Sanofi's Aubagio.
研究与报告
2026年9月14日•1 分钟阅读
Altheogen signs fourth ALT‑B4 licensing deal of 2024 with Novartis
Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.
研究与报告
2026年9月14日•1 分钟阅读
Ewha Aortic Vascular Hospital and FlowNix Sign MOU to Co‑Develop Integrated Aortic Care Solution
Ewha Aortic Vascular Hospital and imaging firm FlowNix have agreed to jointly develop an integrated solution covering the full clinical workflow for aortic patients, from diagnosis to long‑term follow‑up.
研究与报告
2026年9月14日•1 分钟阅读
SK Biopharm Deploys 128 Nvidia B200 AI Accelerators for Drug Discovery
SK Biopharm has installed 128 Nvidia B200 AI accelerators, delivering 576 PFLOPS to boost AI-driven drug candidate discovery and translational research.